4-[(methoxylmethyl)oxy]-3-methoxybenzyl isothiocyanate | 289903-62-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-[(methoxylmethyl)oxy]-3-methoxybenzyl isothiocyanate
• 英文别名: 4-isothiocyanatomethyl-2-methoxy-1-methoxymethoxy-benzene；4-(isothiocyanatomethyl)-2-methoxy-1-(methoxymethoxy)benzene
• CAS: 289903-62-4
• 化学式: C₁₁H₁₃NO₃S
• 分子量: 239.295
• InChiKey: KMTIMNKWVVOLJG-UHFFFAOYSA-N

物化性质

• 沸点：
  357.9±37.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[(methoxylmethyl)oxy]-3-methoxybenzyl isothiocyanate 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 异丙醇 、 乙腈 为溶剂， 反应 16.5h， 生成 1-(1-Benzyl-6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-3-(4-hydroxy-3-methoxy-benzyl)-thiourea
  参考文献：
  名称：

  Aminotetralin-derived urea modulators of vanilloid VR1 receptor

  摘要：

  该发明涉及辣椒素受体VR1配体。更具体地，该发明涉及β-氨基四氢萘衍生的脲类化合物，它们是VR1的有效拮抗剂或激动剂，对于治疗和预防哺乳动物的炎症和其他疼痛症状具有用处。

  公开号：

  US20030236280A1
• 作为产物：
  描述：

  3-甲氧基-4-(甲氧基甲氧基)苯甲醛 在 sodium tetrahydroborate 、 叠氮磷酸二苯酯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三苯基膦 、 lithium chloride 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 反应 4.0h， 生成 4-[(methoxylmethyl)oxy]-3-methoxybenzyl isothiocyanate
  参考文献：
  名称：

  Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands

  摘要：

  The chiral isomers of the two potent simplified RTX-based vanilloids, compounds 2 and 3, were synthesized employing highly enantioselective PTC alkylation and evaluated as hTRPV1 ligands. The analysis indicated that the R-isomer was the eutomer in binding affinity and functional activity. The agonism of compound 2R was comparable to that of RTX. Docking analysis of the chiral isomers of 3 suggested the basis for its stereospecific activity and the binding mode of 3R. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.064

文献信息

• Structure–activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding
  作者：Jeewoo Lee、Su Yeon Kim、Soyoung Park、Ju-Ok Lim、Ji-Min Kim、Myungshim Kang、Jiyoun Lee、Sang-Uk Kang、Hyun-Kyung Choi、Mi-Kyung Jin、Jacqueline D Welter、Tamas Szabo、Richard Tran、Larry V Pearce、Attila Toth、Peter M Blumberg

  DOI：10.1016/j.bmc.2003.12.005

  日期：2004.3

  homovanillate and N'-(4-hydroxy-3-methoxybenzyl) thiourea derivatives that were potent VR1 agonists with high-affinities and excellent analgesic profiles. The design of these simplified RTX analogues was based on our RTX-derived pharmacophore model which incorporates the 4-hydroxy-3-methoxyphenyl (A-region), C(20)-ester (B-region), orthophenyl (C1-region) and C(3)-keto (C2-region) groups of RTX. For the purpose

  我们先前描述了一系列N-（3-酰氧基-2-苄基丙基）高香草酸酯和N'-（4-羟基-3-甲氧基苄基）硫脲衍生物，它们是具有高亲和力和出色的镇痛作用的有效VR1激动剂。这些简化的RTX类似物的设计基于我们的RTX衍生的药效团模型，该模型包含了4-羟基-3-甲氧基苯基（A区），C（20）酯（B区），邻苯基（C1区）和RTX的C（3）-酮（C2-区域）组。为了优化前导激动剂（1-4）上四个主要药效基团的空间排列，我们通过延长或缩短一个碳原子来修饰母体C区3-酰氧基-2-苄丙基的距离改变药效基团之间的距离。我们发现，酰胺中的两个4和19具有EC（50）值< 1 nM用于诱导VR1-CHO细胞中的钙内流。如前所述，抑制RTX与VR1结合和诱导钙摄取的结构活性关系是截然不同的，大概反映了内在和方法上的因素。为了找到VR1配体的活性构象，确定了七个选定激动剂的能量最小构象，并将其四个药效团的位置与五个低能
• [EN] AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR<br/>[FR] MODULATEURS DE L'UREE DERIVES DE L'AMINOTETRALINE DU RECEPTEUR VANILLOIDE VR1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2003097586A1

  公开（公告）日：2003-11-27

  This invention is directed to vanilloid receptor VR1 ligands of formula (1). More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

  本发明涉及式（1）的vanilloid受体VR1配体。更具体地，本发明涉及β-氨基四氢萘衍生的尿素，它们是VR1的有效拮抗剂或激动剂，可用于治疗和预防哺乳动物的炎症和其他疼痛症状。
• Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same
  申请人：——

  公开号：US20040063786A1

  公开（公告）日：2004-04-01

  The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions that have such analogues, and their uses as vanilloid receptor agonists and potent analgesics. The present invention provides a pharmaceutical composition for preventing, alleviating or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neutopathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence.

  本发明涉及含有树脂毒素药效团的新型植物辣椒素类似物、具有此类类似物的药物组合物以及它们作为植物辣椒素受体激动剂和强效镇痛剂的用途。本发明提供了一种用于预防、缓解或治疗疼痛、急性疼痛、慢性疼痛、神经病理性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤病、中风、膀胱过敏、肠易激综合征、呼吸系统疾病，如哮喘或慢性阻塞性肺病、皮肤、眼睛或粘膜刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病或紧急性尿失禁的药物组合物。
• AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR
  申请人：Codd Ellen

  公开号：US20080097102A1

  公开（公告）日：2008-04-24

  This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

  本发明涉及辣椒素受体VR1配体。更具体地说，本发明涉及β-氨基四氢萘基脲，它们是VR1的有效拮抗剂或激动剂，用于治疗和预防哺乳动物的炎症和其他疼痛症状。
• N-(3-acyloxy-2-benzylpropyl)-N′-(4-hydroxy-3-methoxybenzyl)thiourea derivatives as potent vanilloid receptor agonists and analgesics
  作者：Jeewoo Lee、Jiyoun Lee、Jiyoung Kim、Soo Yeon Kim、Moon Woo Chun、Hawon Cho、Sun Wook Hwang、Uhtaek Oh、Young Ho Park、Victor E Marquez、Maryam Beheshti、Tamas Szabo、Peter M Blumberg

  DOI：10.1016/s0968-0896(00)00216-9

  日期：2001.1

  A series of N-(3-acyloxy-2-benzylpropyl)-N'-(4-hydroxy-3-methoxybenzyl)thioura derivatives were investigated as vanilloid receptor ligands in an effort to discover a novel class of analgesics. The proposed pharmacophore model of resiniferatoxin, which includes the C-20-homovanillic moiety, the C-3-carbonyl and the orthoester phenyl ring as key pharmacophoric groups, was utilized as a guide for drug design. The compounds were synthesized after several steps from diethylmalonate and evaluated in vitro in a receptor binding assay and in a capsaicin-activated channel assay. Additional evaluation of analgesic activity, anti-inflammatory activity and pungency was conducted in animal models by the writhing test, the ear edema assay, and the eye-wiping test, respectively. Among the new compounds, 23 and 28 were found to be the most potent receptor agonists of the series with K-i values of 19 nM and 11 nM, respectively. Their strong in vitro potencies were also reflected by an excellent analgesic profile in animal tests with ED50 values of 0.5 mug/kg for 23 and 1.0 mug/kg for 28. Relative to capsaicin these compounds appear to be ca. 600 and 300 times more potent. Both 23 and 28 were found to be less pungent than capsaicin based on the eye-wiping test. However, the compounds did not show significant anti-inflammatory activity. A molecular modeling study comparing the energy-minimized structures of resiniferatoxin and 35 demonstrated a good correlation in the spatial disposition of the corresponding key pharmacophores. The thioureas described in this investigation, which were designed as simplified resiniferatoxin surrogates, represent a novel class of potent vanilloid receptor agonists endowed with potent analgesic activity and reduced pungency. (C) 2000 Elsevier Science Ltd. All rights reserved.